Neuland Laboratories Limited
NSE: NEULANDLABMarket Closed • NSE
Day range
52 week range
Neuland Laboratories Limited closed at INR19675.00 (-1.4%) on volume 0.55x its 20-day average, trading 18.78% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -30.5% QoQ
2026-07-24
DIVIDEND Announced
Dividend - Rs 34 Per Share
2025-07-18
DIVIDEND Announced
Dividend - Rs 12 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 26.5%
Low Debt Profile: Debt-to-Equity is comfortable at 0.16x
High Cash Flow Conversion: CFO/PAT averaged 1.02x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 50.7x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 24 Jul 2026 | Dividend | ₹34.00 / share | — | 24 Jul 2026 |
| 18 Jul 2025 | Dividend | ₹12.00 / share | — | 18 Jul 2025 |
| — | Dividend | ₹14.00 / share | — | 12 Jul 2024 |
| — | Dividend | ₹10.00 / share | — | 11 Jul 2023 |
| 15 Jul 2022 | Dividend | ₹5.00 / share | — | 14 Jul 2022 |
| — | Dividend | ₹3.00 / share | — | 29 Jun 2021 |
| 11 Nov 2020 | Dividend | ₹2.00 / share | — | 10 Nov 2020 |
| — | Annual General Meeting | Annual General Meeting | — | 02 Jul 2020 |
| 20 Feb 2020 | Dividend | ₹2.00 / share | — | 18 Feb 2020 |
| — | Dividend | ₹1.20 / share | — | 27 Jun 2019 |
| — | Annual General Meeting | Annual General Meeting | — | 03 Aug 2018 |
| — | Annual General Meeting (Date Revised) | Annual General Meeting (Date Revised) | — | 21 Dec 2017 |
| — | Dividend | ₹2.00 / share | — | 04 Aug 2016 |
| — | Dividend | ₹1.50 / share | — | 06 Aug 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]
IndiaHealthcare
Is Neuland Laboratories Limited Shariah compliant?
Neuland Laboratories Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (1.19%) complies with AAOIFI threshold (≤ 33%).
What is Neuland Laboratories Limited's current valuation relative to peers?
Neuland Laboratories Limited trades at a P/E of 50.7x compared to the sector median of 37x, and a Price-to-Book of 13.5x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.16x. Interest coverage is 20.2x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 5.9% while net profit growth averaged 3.9%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.